目的 探讨子宫腺肌病患者放置左炔诺孕酮宫内缓释系统(LNG-IUS)后的临床效果.方法 2005年7月至2009年10月于海军总医院妇产科门诊对75例子宫腺肌病患者直接放置LNG-IUS,在放置前、放置后3、6、12、24、36个月随访观察痛经评分(视觉模糊评分法VAS)、月经量评分(PBAC)、子宫体积、CA125等多项指标.结果 VAS痛经评分、月经量PBAC评分、子宫体积、CA125均在放置1年和2年时显著低于放置前,其中子宫体积及CA125在放置3年时恢复至放环前水平.结论 LNG-IUS是治疗子宫腺肌病的一种较为有效且安全的方法,但是放置24个月后其功效可能降低.%Objective To investigate clinical therapeutic effect of Mirena (levonorgestrel-intrauterine system, LNG-IUS) treatment for patients with Adenomyosis. Methods Enrolled patients with adenomyosis ( n = 75 ). Dysmenorrhea grading (visual analogue system-VAS) , pictorial blood loss assessment chart (PBAC) for menorrhagia, uterine volume and carbohydrate antigen 125 (CA125) , etc. Were collected from Pre-treatment, 3,6,12, 24 and 36th months after treatment. Results One year and two- year after insertion mirena, VAS, PBAC, uterine volumes and CA125 were significant lower than pre-insertion, uterine volumes and CA125 at three-year after insertion compared with pre-insertion had no significant difference. Conclusion LNG-IUS was an effective and safe treatment for patients with adenomyosis. LNG-IUS therapeutic potency was likely to decrease after 24 months of its placements.
展开▼
